Article - 14/11/2011 BioTeSys GmbH - The basics of substance testing Esslingen-based BioTeSys GmbH is contracted by its clients to determine the bioactive potential of substances and substance mixtures of foods and dietary supplements. Substances are tested whether or not they have a positive effect on human health using a range of chemical analyses, cell-based tests and clinical trials. https://www.gesundheitsindustrie-bw.de/en/article/news/biotesys-gmbh-the-basics-of-substance-testing
Press release - 02/11/2011 Using Viruses to Fight Brain Tumors Parvoviruses can enter and kill cancer cells, but they do not cause disease in humans. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy against dangerous brain tumors that are almost impossible to treat. https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-viruses-to-fight-brain-tumors
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
Dossier - 05/10/2011 Biosimilars: follow-on biologics of innovator biopharmaceutical products As blockbuster biopharmaceuticals go off patent, biosimilars are increasingly competing with them for a market share. However, the production of biosimilars is rather complex and costly. The approval of biosimilars is also subject to many hurdles. Their introduction to the very expensive biopharmaceuticals market is often associated with marginal price reductions.https://www.gesundheitsindustrie-bw.de/en/article/dossier/biosimilars-follow-on-biologics-of-innovator-biopharmaceutical-products
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Article - 29/08/2011 Ute Schepers – the therapeutic potential of small RNAs and molecular transporters Small RNAs can specifically interfere with cellular mechanisms; or more precisely, with the cells’ protein biosynthesis machinery. Scientists have therefore decided to exploit this potential by using small RNAs against cancer cells or cells damaged in other ways. But the question arises as to how the small RNAs can reach the site where their role is to prevent the generation of dangerous proteins. Dr. Ute Schepers and her team from the Karlsruhe…https://www.gesundheitsindustrie-bw.de/en/article/news/ute-schepers-the-therapeutic-potential-of-small-rnas-and-molecular-transporters
Article - 25/07/2011 The mixture is key: what cells like to feed on Dr. Aziz Cayli knows CHO (Chinese hamster ovary) cells so well that he decided to establish his own company in 2005. Prior to establishing CellCa GmbH in the city of Laupheim, Cayli held posts at Roche in Penzberg and Boehringer Ingelheim in Biberach. CellCa is a specialist in upstream processing and with its current total of 15 staff, the company achieved revenues of around two million euros in 2009. We talked with Dr. Aziz Cayli who did his…https://www.gesundheitsindustrie-bw.de/en/article/news/the-mixture-is-key-what-cells-like-to-feed-on
Press release - 30/06/2011 Cancer treatments: New information from fission yeast When a cell divides the genetic information in the chromosomes must be passed on error-free to the daughter cells. Researchers at the Friedrich Miescher Laboratory in Tübingen are studying this process using fission yeast as a model organism. In cooperation with researchers at the University of Tübingen they succeeded in attributing additional tasks to the Aurora enzymes which were already recognized as important cellular tools for the reliable…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-treatments-new-information-from-fission-yeast
Press release - 28/06/2011 Ulcerative colitis: Lipid Therapeutics announces start of Phase IIb clinical trial Lipid Therapeutics, a biotechnology company, announced today that it has initiated a Phase IIb clinical trial with its lead product LT-02 in patients with ulcerative colitis. Lipid Therapeutics received approval for this multi-center, international trial from the authorities in Germany and Lithuania and is awaiting approval in Romania. Patient enrollment has already started in Germany and Lithuania.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulcerative-colitis-lipid-therapeutics-announces-start-of-phase-iib-clinical-trial
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Article - 30/05/2011 From bench to bedside to bench The term translational medicine does not always refer to the concept “from bench to bedside and back”, and indeed is often used to refer to many other, somewhat distant, concepts. However, the new translation centres and translational research consortia do correspond to the original meaning. These new centres and consortia have become effective structures in health research in Germany whose goal is the continuous improvement of the diagnostic and…https://www.gesundheitsindustrie-bw.de/en/article/news/from-bench-to-bedside-to-bench
Article - 30/05/2011 Technology Licensing Office (TLB): invention and patent management The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Press release - 23/04/2011 Liver cell infusion performed for first time in the United States on child with life-threatening disorder The liver cell infusion developed by the Weinheim-based biotechnology company Cytonet GmbH & Co. KG has been granted orphan drug status in the USA. The first American child suffering from urea cycle disorder (UCD) was treated with Cytonet’s liver cell infusion in a clinical trial that began in autumn 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cell-infusion-performed-for-first-time-in-the-united-states-on-child-with-life-threatening-dis
Press release - 22/03/2011 Bringing artifical vision clinical trials to US Retina Implant AG Partners with Wills Eye Institute to Bring Artificial Vision Clinical Trials to the United States. Wills Eye to be the Primary Investigation Site to Offer the Subretinal Approach to Retinitis Pigmentosa Patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bringing-artifical-vision-clinical-trials-to-us
Article - 21/03/2011 Immunotherapy: the rocky road to clinical application Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…https://www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
Press release - 13/03/2011 Vascular stent that dissolves on its own The first ever implant in Germany of a bioresorbable, drug-coated stent in a cardiac patient has been carried out by physicians from the University of Heidelberg. In contrast to traditional metal stents, which remain permanently in the patients’ body, the innovative implant dissolves around two years after the procedure is carried out.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vascular-stent-that-dissolves-on-its-own
Article - 14/02/2011 Affimed’s novel TandAb® antibodies enter clinical development phase With the initiation in October 2010 of a Phase I (“first in man”) study of the tetravalent, bispecific antibody AFM13 based on its proprietary TandAb® technology, Heidelberg-based Affimed Therapeutics AG has become a clinical drug development company. https://www.gesundheitsindustrie-bw.de/en/article/news/affimed-s-novel-tandab-antibodies-enter-clinical-development-phase
Dossier - 07/02/2011 The era of personalised medicine is dawning A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-era-of-personalised-medicine-is-dawning
Press release - 24/01/2011 Synimmune - Close cooperation cuts new cancer drug development time A development project from Synimmune GmbH, founded in July 2010, made a big impression on the panel of assessors at the German Federal Ministry of Education and Research (BMBF). So much so, that the company was awarded EUR 2.5 million as part of the GO-Bio biotechnology start-up scheme. https://www.gesundheitsindustrie-bw.de/en/article/press-release/synimmune-close-cooperation-cuts-new-cancer-drug-development-time
Article - 12/12/2010 Pharmacovigilance: safety becomes a principle Tübingen-based CenTrial GmbH established in 2000 is a provider and manager of clinical trials. Pharmacovigilance is an important segment of the companys work CenTrial supports its clinical trial clients in all phases of clinical drug development related to drug safety up until the time a drug enters the market and beyond. The services offered range from the analysis of data to the complete design of the safety management process including…https://www.gesundheitsindustrie-bw.de/en/article/news/pharmacovigilance-safety-becomes-a-principle
Press release - 06/12/2010 Kihara Foundation Kihara Memorial Yokohama Foundation for the Advancement of Life Sciences called Kihara Foundation was established in 1985 in memory of the late Dr. Hiroshi Kihara a world famous geneticist and evolutionary scientist Professor of Kyoto University for the advancement of Life Sciences.https://www.gesundheitsindustrie-bw.de/en/article/press-release/kihara-foundation
Article - 30/11/2010 Off-label use in children: the problem is known but improvement happens step by slow step The majority of drugs prescribed to children and adolescents have not been specifically licensed for their use. The majority of drugs have been tested and formulated for adults. This so-called off-label practice is associated with greater risks than those one would expect in medicinal therapy. We talked to Michael Kölch senior consultant in the Department of Paediatric and Adolescent PsychiatryPsychotherapy at Ulm University Hospital about this…https://www.gesundheitsindustrie-bw.de/en/article/news/off-label-use-in-children-the-problem-is-known-but-improvement-happens-step-by-slow-step